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Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) that require hospitalisation are 
important events for patients. Functional impairment and skeletal muscle dysfunction can increase 
the risk of hospitalisation and readmission, independent of lung function. In addition, once a patient 
is admitted multiple factors can lead to worsening outcome including immobility, systemic 
inflammation and nutritional depletion. These non-pulmonary factors are potentially amenable to 
exercise therapy, as part of pulmonary rehabilitation. Peri-exacerbation pulmonary rehabilitation 
has an important role in the management of exacerbations of COPD.
In this review we explore how functional limitation and skeletal muscle dysfunction affects patients 
having a severe exacerbation of COPD, the systemic impact of hospitalisation on patients including 
potential aetiologies and the role of pulmonary rehabilitation around the time of an exacerbation. 
This includes rehabilitation during the inpatient phase, post-exacerbation rehabilitation and 
rehabilitation bridging hospital discharge. We also describe potential future developments in peri-
exacerbation pulmonary rehabilitation.
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Introduction
Worldwide, COPD constitutes one of the largest health burdens with 3.17 million deaths in 20151. In 
the UK, an estimated 1.2 million people (2% of the population) have diagnosed COPD making it the 
second commonest lung disease, after asthma2. 
The natural history of COPD is punctuated by acute episodes of worsening symptoms and increased 
airways inflammation known as exacerbations and are a major priority in the treatment of COPD. For 
an individual with COPD it results in marked worsening of symptoms and disease burden, far beyond 
the burden when in the stable state. It is also now clear that certain individuals are prone to 
recurrent exacerbations- known as the frequent exacerbator phenotype3. The strongest predictor of 
future exacerbations is a history of previous exacerbation. Patients with severe exacerbations 
requiring admission to hospital demonstrate this high risk, with 43% of patients in the UK readmitted 
within three months4. For healthcare organisations exacerbations account for more than half of all 
COPD costs. As well as considerable expense, the challenge on healthcare systems provide a logistic 
challenge, with exacerbations accounting for over a million bed days each year across the UK, 
presenting in an unpredictable fashion2. 
The primary pathophysiology of COPD is within the lungs and the diagnosis of COPD is confirmed by 
detecting airflow limitation using spirometry. However, over the past decades it has been 
increasingly recognised that COPD has a number of extra-pulmonary manifestations that have 
considerable impact on patients and the disease burden. Exercise limitation is a key symptom of 
COPD. It is clear that this is in part driven through leg fatigue and skeletal muscle dysfunction, with 
quadriceps function being an independent marker of mortality5. 
Muscle dysfunction is more common in patients with advanced COPD, as are exacerbations of COPD. 
The combination of these two aspects of COPD may have important consequences, as well as 
specific therapeutic interventions. In this review we describe the functional limitation and skeletal 
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muscle dysfunction in patients hospitalised for an exacerbation of COPD, the acute systemic effects 
on hospitalisation and the role of peri-exacerbation pulmonary rehabilitation. 
The Impact of Skeletal Muscle Dysfunction and Functional Impairment on Exacerbations of COPD
Independent of disease severity, systemic markers of disease may increase the risk for patients to be 
admitted to hospital with an exacerbation. Physical inactivity and increased sedentary time are well 
recognised and described in COPD. Patients with reduced physical activity are at an increased risk of 
hospital admission, readmission to hospital following an index admission and death6, 7. These studies 
have corrected for factors, such as disease severity and symptom burden.
Functional measures, such as the six minute walk test, have been shown to be predictive of 
hospitalisation and prognosis. Indeed the most commonly used prognostic tool, the BODE score, is 
part comprised of walking distance8. The Four meter Gait Speed (4MGS) is a well validated measure, 
and a key part of the frailty assessment9, 10. In patients hospitalised with an exacerbation of COPD, 
4MGS taken at the time of discharge is a marker of readmission, independent of disease severity11.
Low skeletal muscle mass is also known to be an independent risk factor for hospital admission and 
mortality. Body mass index (BMI) is a crude measure of body composition, and like 6MWT, is one of 
the components of the BODE score, which predicts hospitalisation and mortality12. Direct measures 
of the skeletal muscle, such as the fat free mass and quadriceps function, have been shown to be a 
better prognostic indicator than BMI13, 14. In those admitted to hospital, patients with the smallest 
muscles measured at the bedside using ultrasound are more likely to be readmitted or die, 
independent of other markers of disease severity or risk of readmission15.
Systemic Consequences of Exacerbations of COPD
Exacerbations of COPD present as increasing dyspnoea as a result of increased airways inflammation 
and require additional therapy to treat the lung. However, it is clear that exacerbations impact 
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various body systems with a number of acute non-pulmonary effects. Similar to stable disease, the 
skeletal muscle system and function to walk are important factors affected during the exacerbating 
state. In particular severe exacerbations, which require admission to hospital, have a profound 
effect with multiple insults all contributing to adverse impact on the whole body. This leads to a 
number of important consequences, such as reduced ability to protect against future insults, i.e. 
reduced resilience, and increased risk of hospital readmission and death (figure 1).
figure 1 here
Factors that impact on Systemic Factors of COPD in Exacerbations
Immobility
Enforced bed rest has been used as a treatment since the 19th century for a range of medical 
conditions since Victorian times including hysteria16 and tuberculosis17. Bed rest has continued as a 
mainstay of therapy until the late 20th century18. As such public perception of bed rest as therapy 
for acute illness continues to today. 
Bed rest studies in healthy populations have shown significant reductions in both young19 and 
older20 healthy volunteers, with larger decreases in the muscles of ambulation compared to other 
muscle groups 19. These findings are echoed in the critical care population with acute skeletal muscle 
loss21 and persistent long-term functional deficit22, 23.
Whilst the effects of acute immobility are well recognised in those previously fit and well, the effects 
may be more marked in those with long-term conditions. In patients with COPD in the stable state 
there is preferential loss of oxidative type 1 muscle fibres and loss of mitochondria, which may 
impede the ability to protect against the detrimental effects of bedrest24, 25. In the acute care setting 
patients with COPD have increased symptoms of fatigue26 and breathlessness, resulting in them 
having the perception of being too ill or frail or disabled to take part in physical activity26. 
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Systemic inflammation
The mechanisms for the systemic effects of COPD are varied and multi-factorial. It has been shown 
that a sub-set of patients with COPD have an excess of systemic inflammation and those with 
persistent systemic inflammation have a poorer prognosis and are more prone to exacerbation27. 
Systemic inflammation has also been linked with increased risk of co-morbidities, such as 
cardiovascular disease28. 
At the time of exacerbations, systemic inflammation is particularly marked even in those without 
persistent inflammation. In the most severe exacerbations, such as those undergoing hospitalisation, 
inflammatory markers measures such as C - reactive protein are increased to a mean of 81 mg/l (SD 
99)29. 
An increased systemic inflammatory response is associated with worse skeletal muscle function, 
with higher circulating Interleukin-8 associated with lower quadriceps strength30. Whether this 
inflammatory effect directly impacts on skeletal muscle or is an associated inflammatory response 
based on severity of exacerbation is unknown. Indeed, no increase in inflammatory cells are seen in 
quadriceps muscle at the time of exacerbation, questioning the direct impact of inflammation on 
acute muscle dysfunction31.
Nutritional depletion
Involuntary weight loss, prevalent in patients with advanced COPD, is a well-recognised poor 
prognostic factor32-34 and is associated with higher mortality35. 
Weight loss in COPD is multifactorial, with reduced oral intake, increased work of breathing and 
associated systemic inflammation. Acutely, exacerbations increase basal metabolic expenditure, 
when unmatched with adequate caloric intake can lead to nutritional depletion, muscle wasting and 
dysfunction36. Although nutritional supplementation in stable cachectic COPD patients is 
recommended, studies on nutritional repletion in the acute state have not shown efficacy. 
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Vermeeren et al demonstrated no additional improvements in lung function or muscle strength with 
caloric supplements during exacerbations37. Rutten et al described loss of intestinal integrity in COPD 
patients, so profound it was suggested that this is added as a new component in the multisystem 
disorder, and that simply increasing calorie intake may be inadequate38. 
Hospital-Associated Disability
The detrimental effects described above lead to a loss of physical function (figure 2). In addition to 
this, patients in hospital have altered sleep patterns, acute cognitive impairment and loss of 
autonomy. The resulting syndrome has been described as a number of phenomena, including 
hospital-associated disability, hospital acquired disability and post hospitalisation syndrome. 
Hospital-associated disability (HAD) is described in the geriatric population as a loss of activity of 
daily living (ADL) due to admission to hospital39. HAD may take months to recover or lead to 
irreversible changes. Despite the clinical recognition of the problem the process and natural history 
of HAD is poorly understood. Whilst HAD has been most widely described in the geriatric population 
it is likely to be a key component in chronic diseases, including COPD.
Figure 2 here
Rationale for exercise training
Currently the treatment for exacerbations of COPD is mainly focused on the primary insult to the 
lungs. Exercise therapy potentially lends itself to the treatment of HAD and patients with advanced 
COPD and pre-existing functional limitation.
Pulmonary rehabilitation in the stable setting is one of the highest value therapies in COPD and is 
recommended worldwide in symptomatic patients40, 41. Pulmonary rehabilitation consists of 
individualised exercises, educational and behavioural elements targeted at minimising symptom 
burden, maximising exercise performance, promoting autonomy and enhancing quality of life 40. 
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Therefore applying pulmonary rehabilitation around the time of an exacerbation, also known as 
peri-exacerbation pulmonary rehabilitation, has been trialled and is now internationally 
recommended. The remainder of this review will examine the evidence for pulmonary rehabilitation 
initiated following hospitalisation for an exacerbation of COPD-post exacerbation pulmonary 
rehabilitation (PEPR), pulmonary rehabilitation initiated during hospitalisation, and possible future 
developments.
Post Exacerbation Pulmonary Rehabilitation
PEPR has had a major impact on the treatment of severe exacerbations of COPD and is 
recommended in both National and International guidelines40, 41. Trials of PEPR have typically 
performed PR programmes similar in structure and duration to PR programmes in the stable state, 
but within the recovery period from severe exacerbations (defined as requiring hospitalisation).
The first randomised controlled trial to investigate PEPR was Man et al in 200442. 42 patients were 
recruited within 10 days of discharge from hospital and underwent an eight week PR programme. In 
this landmark study, patients in the usual care group had not recovered at eight weeks, with a 
median incremental shuttle walk (ISWT) of only 90 meters. In comparison patients who underwent 
PEPR ISWT improved by 90m, double the minimal clinically important difference. Large clinically and 
statistically significant differences were also noted in health related quality of life. 
The results of Man et al have been replicated in a number of other similar sized trials (Murphy 2005, 
Ghanem 2010, Deepak 2014), which use a similar model of 2-3 supervised exercise sessions per 
week starting following discharge43-45. A number of the trials have used supervised home-based 
exercise, rather than in a formal setting, potentially increasing uptake of patients who do not need 
to travel43, 45, 46. Only one trial (Ko et al 201147) did not show benefit of PEPR in terms of exercise 
capacity or health related quality of life.
One of the secondary outcome measures in the trial by Man et al was readmission to hospital. The 
PEPR group had a significant reduction in rate of hospital admission at 3 months. The rationale, as 
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described above, was likely to be training the non-pulmonary deficits occurring following 
exacerbation and increasing resilience. Seymour et al48, part of the same research group as Man et al 
performed a larger RCT, powered to detect a significant reduction in readmission to hospital. They 
recruited 60 patients in a similar model across four hospitals in London. Exercise capacity, 
quadriceps strength, health related quality of life improved similarly to the previous trial. An 85% 
reduction in hospital readmission in the PEPR group was seen during the intervention period. 
The largest trial of PEPR was reported by Ko et al in 201746. PEPR was a component of a larger 
comprehensive care programme, which also included specialist medical review, telephone support 
line, and regular specialist follow-up. 180 patients were included in the study. 33% (n=30) of the 
intervention group received supervised outpatient physiotherapy and 67% (n=60) unsupervised 
home exercise. Similar to the Seymour study a significant reduction in the rate of hospital 
readmissions was seen in the intervention group (incident rate ratio 0.668), with the greatest 
difference seen in the first three months. Improvements were also seen in health related quality of 
life questionnaires, but not in exercise capacity.
The strength of these trials has unequivocally shown strong efficacy of PEPR for severe 
exacerbations of COPD. However, real-life clinical implementation has proven more challenging. 
Recruitment and patient uptake of PEPR has been low in the UK. Jones et al demonstrated that only 
9.6% of participants received and completed PEPR despite an active Pulmonary Rehabilitation 
service49. This low uptake had been indicated in Seymour et al who took three years to recruit 60 
patients across four London hospitals48. Therefore, strategies to improve uptake to PEPR or 
alternative models of delivering treatment are needed.
Pulmonary Rehabilitation and Exercise Training During the Hospitalisation
As described above trials of PEPR have yielded considerable benefits for the patients who attend a 
programme. Whilst it helps the recovery from the impact of hospital associated disability and the 
impact of the exacerbation, it does not prevent or minimise the primary loss of physical function. In 
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order to target this, intervention may be required to start during the period of hospitalisation, 
ideally as early as possible. Due to nature of a severe exacerbation and acute illness of inpatients 
conventional models of pulmonary rehabilitation programmes are difficult to implement and 
interventions have been highly varied. For the purposes of this review we have considered exercise 
interventions performed during the hospitalisation only (i.e. ended at time of discharge), including 
non-volitional techniques such as neuromuscular electrical stimulation (NMES) and training that 
includes both during the inpatient and post-discharge periods.
Training during the inpatient phase only
Two trials of inpatient rehabilitation reported outcomes 20 years ago50, 51. Nava et al recruited 80 
patients in a respiratory intensive care unit with COPD. Length of hospital stay in these patients was 
more than one month. Those who received exercise intervention (comprising progressive aerobic 
training and respiratory muscle training) improved their walking capacity, whereas those in the usual 
care group (not including aerobic training) had no improvement in walking. Baseline measures were 
conducted as soon as patients were able, as 76% had required mechanical ventilation initially50. 
Kirsten et al also demonstrated improvements in walking capacity following aerobic training over 
usual care in 29 patients admitted with an exacerbation of COPD. Both trials delivered their 
intervention later in the admission, following initial recovery; Kirsten et al starting at days 6-8 of 
admission and Nava et al once able to perform cycling51.
More recently Troosters et al52 used resistance training to target the skeletal muscle to prevent loss 
of quadriceps strength. Patients were recruited in their first day on a respiratory ward and 
underwent a mean of 6 days of training, initially at 70% of 1 repetition max (1RM). Efficacy was 
shown with a 10% increase in strength in the intervention group. This was sustained at one month 
following discharge. Improvement in 6MWT was also seen in the intervention group, though this 
was not statistically different to the control group. No difference in hospitalisation rate was seen at 
six months.
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He et al53 also recruited patients on their second day of admission in 101 patients admitted with 
COPD. Patients underwent twice daily aerobic and resistance training. Those who received inpatient 
training improved their 6MWT, whereas those who had usual care showed no difference, though 
between groups were not reported. 6MWT on at time of admission was relatively well preserved 
(approximately 250m) and duration of intervention was not reported. In a similar study Liao et al54 
performed twice daily aerobic and resistance training for four days in 61 patients admitted with an 
exacerbation. Large increases (120m) in 6MWT were seen in the intervention group but not the 
control group. Similar improvements were also seen in dyspnoea.
Overall short-term the trials have shown that supervised training in patients who are inpatients 
benefit in terms of function, though the longer term effects are unknown.
Non-Volitional training
With the increased symptom burden at the time of an exacerbation training techniques that reduce 
the ventilatory burden of training are attractive. Neuromuscular electrical stimulation (NMES) 
directly stimulates skeletal muscle using electrical current resulting in muscle contraction with 
minimal ventilatory demand55. NMES has been used in the stable state in COPD and showed short 
term improvements in muscle function. While the effects are short-lived, it may be well placed to 
bridge the acute hospital admission before PEPR. Three trials have explored the use of NMES in the 
peri-exacerbation period; one in the intensive care unit 56, one during hospitalisation on a medical 
ward57 and one in a rehabilitation unit following hospitalisation58. All three trials showed short-term 
benefit of NMES clinical efficacy in terms of statistically significant differences in muscle quadriceps 
strength and walking distance. However, use of NMES in the clinical setting at this time are unlikely 
as conclusions using this modality are limited with small numbers of patients in all trials.
Training crossing both inpatient and outpatient phase
Page 12 of 28
Editorial Office: respirology@resphealth.uwa.edu.au; Editors-in-Chief: Philip Bardin and Paul Reynolds
Respirology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL for peer review only
Several trials have attempted to cover the wider peri-exacerbation period, including both during 
hospitalisation and the post-hospitalisation recovery period59-61. In the earliest trial by Behnke et al, 
30 participants underwent 10 days of inpatient training, followed by six months of unsupervised 
home-based training59. They were recruited during the recovery phase of the admission (days 4-7). 
In a per-protocol analysis (65% of recruited patients) significant improvements in walking 
performance and symptoms were seen in the intervention group, when compared with the control 
group. The differences in exercise capacity were seen in the first 10 days of intervention, with an 
improvement in the intervention group of 225m on the 6MWT, but no change in the control group. 
Two other, more recent trials, have trialled the wider peri-exacerbation period. Both are two of the 
larger RCTs in the field of peri-exacerbation pulmonary rehabilitation and also attempted to recruit 
earlier into the hospitalisation than the Behnke trial. Eaton et al60 recruited 97 patients which 
included inpatient rehabilitation followed by a standard PEPR programme. No difference was seen 
between groups, for hospital readmission, exercise capacity or quality of life. However, in the per-
protocol sub-analysis of the 19 participants who attended the PEPR aspect a reduction in hospital 
readmission was seen, providing encouraging results.
In the largest trial in the peri-exacerbation pulmonary rehabilitation literature Greening et al61 
incorporated several inpatient aspects of therapy including NMES, resistance training and aerobic 
training. Following hospital discharge, in an attempt to increase participation and stop the high 
drop-out associated with PEPR a home-based programme with telephone support, but unsupervised 
training was provided. 389 participants were recruited. However, length of hospital stay was lower 
than in other trials (median 5 days), meaning the inpatient (supervised) intervention was limited. 
The home-based programme was poorly adhered to. Similar to Eaton et al, no between group 
differences in exercise capacity, health status or hospital readmission were seen. Surprisingly, 
separation in mortality was seen starting more than 6 months after the intervention finished, in 
favour of the usual care group. This is unlikely to be due to the intervention, as was separated 
temporally from the intervention. No signal was seen in the per-protocol analysis and is more likely 
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explained by case-mix of the groups, as those in the intervention group had higher baseline MRC 
score. Patients in the intervention group were also less likely to uptake standard supervised 
pulmonary rehabilitation after three months which may have impacted longer term outcomes.
Another key difference in both the Eaton and Greening trials was that large increases in exercise 
capacity and quality of life in usual care group were observed. This is different from other reported 
trials, where the control groups have remained unimproved months later. In the trial by Greening et 
al the usual care groups received daily ward-based physiotherapy, as per usual UK practice, which 
may also explain the recovery seen in the usual care groups and lack of benefit with additional 
rehabilitation strategies.
Trials of peri-exacerbation pulmonary rehabilitation that include both inpatient and outpatient 
training have so have proven less successful than trials focussing on either the inpatient or 
outpatient components. Difficulties in adapting training across changing environments, without 
resulting in large drop-out need to be addressed before this is likely to be as successful as other 
areas of peri-exacerbation pulmonary rehabilitation.
Table 1 here
Peri-Exacerbation Pulmonary Rehabilitation in Non-COPD Patients
Until the last few years research in pulmonary rehabilitation in the stable state has almost 
exclusively focussed on COPD. Echoing this, peri-exacerbation pulmonary rehabilitation has not been 
trialled in non-COPD respiratory conditions. However, the rationale for it is no less strong in other 
respiratory conditions as it targets the non-pulmonary elements of the disease, other respiratory 
conditions experience exacerbations, and is effective in other conditions in the stable state. 15% of 
patients in Greening et al61 had other chronic respiratory diseases (bronchiectasis, interstitial lung 
disease and chronic asthma) with no difference in outcome between those with COPD and those 
who didn’t. Trials in other respiratory conditions such as bronchiectasis are underway and awaited62.  
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Similarly, rehabilitation around the time of hospitalisation has been successfully implemented in 
other diseases and elderly populations63, 64. 
The Future Direction of Peri-Exacerbation Pulmonary Rehabilitation
More so than pulmonary rehabilitation in the stable state, peri-exacerbation pulmonary 
rehabilitation has a number of unanswered questions and is likely to evolve over the next few years. 
PEPR has the best efficacy, but with poor uptake has limited application to the wider population. 
Strategies to increase uptake to post-exacerbation pulmonary rehabilitation are therefore 
important. One pragmatic approach to increasing uptake post-exacerbation rehabilitation would be 
to delay the start of rehabilitation until recovery from the hospitalisation is complete, when patients 
may be more willing to attend classes. This would ensure increased participation in pulmonary 
rehabilitation in a high-risk, symptomatic population who would gain benefit from a more standard 
programme of pulmonary rehabilitation. Trials comparing early and late post exacerbation 
pulmonary rehabilitation have proven challenging65, 66. One trial showed no long-term difference 
between patients recruited to either immediate post exacerbation pulmonary rehabilitation or six 
months later, but recruited only 15% of its total planned population66. Results of other ongoing trials 
of early versus late pulmonary rehabilitation are awaited67. 
Reasons for lack of uptake to PEPR are numerous, linked to both patient perceptions of their current 
illness and high risk of early hospital readmission26. Health coaching following hospitalisation has 
recently been shown as a possible intervention to address these aspects. In a study by Benzo et al68 
patients received a motivational interviewing based health coaching intervention. During the 
intervention period there was a reduction in hospital readmission rate, as well improvements in 
health related quality of life. No difference in physical function was found. Techniques such as health 
coaching, may therefore work as a bridge to pulmonary rehabilitation, which may then offer 
additional benefits, such as increased exercise capacity and longer term benefits.
Page 15 of 28
Editorial Office: respirology@resphealth.uwa.edu.au; Editors-in-Chief: Philip Bardin and Paul Reynolds
Respirology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL for peer review only
Growing internet use and web literacy, including among the older population make web-based 
interventions a potential avenue. Successful trials in the stable state have been published and may 
allow patients who struggle to attend rehabilitation programmes during the recovery phase a more 
structured and supervised home-based programme69. However, increased transient cognitive 
impairment is common in the recently hospitalised population70 and may impact on the ability to 
deliver more self-management directed interventions. Web literacy may also be lower than reported 
in this population71.
Improving the inpatient aspect of rehabilitation also requires further research. The acuity of the 
illness may prevent training similar to an outpatient PR programme, with some trials struggling to 
recruit72, but other strategies may continue to develop. Anabolic agents have been trialled in the 
stable state73, 74, including those with advanced disease75. Whilst effective at increasing muscle mass, 
a lack of functional improvement above exercise therapy has limited their use in the stable state. 
However, in the early acute care setting they may be able to protect against HAD when ability to 
exercise may be limited. 
Summary
Acute exacerbations of COPD are a major event for patients with COPD. They have considerable 
adverse effects on the whole body, which is historically not treated with medical therapy. Post-
exacerbation pulmonary rehabilitation offers excellent efficacy and improvements in exercise 
capacity, health related quality of life and reduced readmission to hospital76. Strategies to improve 
uptake to PEPR are needed however, as this has been limited. Interventions during the 
hospitalisation seem to offer short term functional benefit, but trials attempting to cross both 
inpatient and outpatient settings have been limited, probably due to lack of supervised training. In 
summary it is important that all potentially eligible patients are given every opportunity and support 
to enrol in pulmonary rehabilitation programme following an exacerbation of COPD.
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List of Figures
Figure 1: Multi-factorial insults and consequences on individuals following admission to hospital with 
an exacerbation of COPD. Blue markings demonstrate a selection of non-pulmonary organs affected 
(heart, skeletal muscles, bone/spine, pancreas, brain)
Figure 2: Schematic of time-course of hospital associated disability, including symptoms, insults and 
function
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Table 1: Randomised controlled trials of peri-exacerbation pulmonary rehabilitation
Outcome of ResultsStudy n= Follow up
Primary 
Outcome Healthcare Utilisation Exercise capacity/ Strength Symptoms
In-patient AECOPD
Nava50 80 Hospital discharge Exercise capacity
Length of hospital stay:
No difference
6MWT: 
Improved in intervention but not 
control group. 
Groups not compared.
Dyspnoea: 
Improved in both groups.
 Groups not compared
Kirsten51 29 10 days Exercise capacity Not reported
6MWT & minute ventilation:
Greater improvement in the 
intervention group
Dysnpnoea:
Greater improvement in the 
intervention group
Troosters52 36 1 month Quadriceps force
Hospital readmission:
No difference at 6 
months
Quadriceps strength: 
Greater improvement in 
intervention group.
6MWT: 
No difference between groups
Not reported
Abdellaoui56 15 6 weeks Quadriceps strength Not reported
Quadriceps force & 6MWT:
Greater improvement in the 
intervention group
Not reported
Giavedoni57 11 14 days Quadriceps strength Length of hospital stay:No difference
Quadriceps force:
Greater improvement in the 
intervention group
Not reported
Borges77 29 30 days Quadriceps strength Not reported
6MWT & strength:
Greater improvement in the 
intervention group
SGRQ:
No difference between groups
He53 97 Hospital discharge Exercise capacity    Not reported
6MWT: 
Improved in intervention but not 
control group. 
Groups not compared.
CRQ & ADL: 
Improved in intervention but not 
control group. 
Groups not compared.
Liao54 61 4 days Dyspnoea Not reported
6MWT:
Greater improvement in the 
intervention group
Dysnpnoea:
Greater improvement in the 
intervention group
In-patient progressing to Out-Patient AECOPD
Behnke59 46 6 months Exercise capacity Not reported
6MWT:
Greater improvement in the 
intervention group
CRQ:
Greater improvement in the 
intervention group
Eaton60 97 3 months Re-admission Hospital readmission:No difference
6MWT:
No difference between groups
CRQ:
No difference between groups
Greening61 389 12 months Re-admission Hospital readmission:No difference
ISWT & Quadriceps strength:
No difference between groups
SGRQ:
No difference between groups
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Cox78 58 90 days Exercise capacity Hospital readmission:No difference
6MWT:
No difference between groups
CAT:
No difference between groups
Out-patient AECOPD
Man42 42 8 weeks Exercise capacity
Hospital readmission:
No difference between 
groups
ISWT:
Greater improvement in the 
intervention group
CRQ & SGRQ:
Greater improvement in the 
intervention group
Murphy43 26 6 weeks Exercise capacity
Exacerbation:
No difference at 3 or 6 
months between groups
ISWT: 
Improved in intervention but not 
control group. 
Groups not compared.
SGRQ: 
Improved in both groups.
 Groups not compared
Vivodtzev58 17 4 weeks Quadriceps strength Not reported
Quadriceps force & 6MWT:
Greater improvement in the 
intervention group
Dysnpnoea:
Greater improvement in the 
intervention group
Seymour48 60 3 months Re-admission
Hospital readmission:
Fewer readmissions in 
intervention group
ISWT & quadriceps force:
Greater improvement in the 
intervention group
SGRQ:
Greater improvement in the 
intervention group
Ghanem45 39 2 months Exercise capacity Not reported
6MWT:
Greater improvement in the 
intervention group
CRQ:
Greater improvement in the 
intervention group
Puhan66 36 18 months Exacerbations Exacerbation:No difference Not reported
CRQ:
No difference between groups
Ko (2011)47 60 12  months Re-admission
Hospital Readmission:
No difference between 
groups
6MWT & VO2max:
No difference between groups
SGRQ:
Greater improvement in the 
intervention group
Deepak44 60 3 months Exercise capacity Not reported
6MWT:
Greater improvement in the 
intervention group
SGRQ:
Greater improvement in the 
intervention group
Ko (2017)46 180 12 months Re-admission
Hospital readmission:
Fewer readmissions in 
intervention group
6MWT:
No difference between groups
SGRQ:
Greater improvement in the 
intervention group
6MWT=six-minute walk test;  VO2max=oxygen consumption; ISWT=incremental shuttle walk test; CRQ=chronic respiratory questionnaire; SGRQ= St. Georges respiratory Questionnaire; ADL 
scale=Activity of Daily Living
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Figure 1: Multi-factorial insults and consequences on individuals following admission to hospital with an 
exacerbation of COPD. Blue markings demonstrate a selection of non-pulmonary organs affected (heart, 
skeletal muscles, bone/spine, pancreas, brain) 
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Schematic of time-course of hospital associated disability, including symptoms, insults and function 
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